Inogen Q1 revenue rises on international demand

Inogen

07/05/2026 21:47

Overview

US respiratory device maker's Q1 revenue grew 3.4% yr/yr, driven by international demand

Company authorized $30 mln share repurchase program

Inogen reiterated full-year 2026 revenue guidance

Outlook

Inogen expects Q2 2026 revenue between $94 mln and $97 mln

Company reiterates full-year 2026 revenue outlook of $366 mln to $373 mln

Inogen remains committed to driving positive adjusted EBITDA improvement in 2026

Result Drivers

INTERNATIONAL SALES - Higher demand for portable oxygen concentrators in international markets and favorable foreign exchange rates offset lower U.S. sales and rentals

COST IMPROVEMENTS - Adjusted gross margin rose due to cost improvements in total cost of revenue

R&D INVESTMENT - Increased research and development spending contributed to a negative adjusted EBITDA

Company press release: ID:nBw1f2SdJa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$85.10 mln
$82.35 mln (2 Analysts)
Q1 Adjusted Net Income
Beat
-$4 mln
-$7.70 mln (2 Analysts)
Q1 Net Income
-$8.30 mln
Q1 Adjusted EBITDA
Miss
-$1.40 mln
-$1.35 mln (2 Analysts)
Q1 Gross Margin
44.50%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inogen Inc is $12.00, about 68.8% above its May 6 closing price of $7.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)